Clinical Trial Update: Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063) [Phase 3]

View source ↗

Summary

Phase 3 study of MK0869 (0869-063) for major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• MK0869 (0869-063) (MK0869)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED